OMIDRIA Special Ep. 3 Performance and Clinical Outcomes of OMIDRIA in Cataract Surgery
Wednesday, 26 July 2023
Dr Arjan Hura (host)
Dr Arjan Hura is a cataract, refractive, and anterior segment surgeon at the Maloney-Shamie Vision Institute in Los Angeles, CA. Dr. Hura is committed to the American Academy of Ophthalmology‘s mission of protecting sight and empowering lives. His research and clinical interests include working with the latest cutting-edge technology to constantly try to improve patient outcomes.
Dr Denise Visco (guest)
Dr Denise Visco is an ophthalmologist in York, Pennsylvania and is affiliated with UPMC Memorial. Dr. Visco is a pioneer of surgical advancement being the first female surgeon in the world to perform cataract surgery with the LENSAR Advanced Laser Cataract System. She is also the first in the area to offer all laser LASIK procedures and customized options for cataract surgery.
Dr Steven Silverstein (guest)
Dr. Steven Silverstein is a board-certified ophthalmologist and fellow of the American College of Surgeons.
This episode of ‘Peer2Peer: The Podcast’, focuses on clinical performance and results from studies conducted with OMIDRIA®(phenylephrine and ketorolac intraocular solution) 1%/0.3%, in cataract surgery. The episode, featuring Dr. Denise Visco and Dr. Steven Silverstein, highlights the potential advantages of OMIDRIA in cataract surgery shown by rigorous clinical trials, including improved patient compliance, reduction in post-operative drops, and reduced reliance on pain medications, without increasing the risk of complications.
- The use of OMIDRIA in cataract surgery reduces the intraoperative need for pain medications2: Dr. Visco’s research, where OMIDRIA replaced steroids in the operating room for some of the patients, showed that CME was three times less likely for patients who had received OMIDRIA. Patients where steroids had been used were also twice as likely to appear for post-op visits for photophobia or rebound iritis, with no adverse effects from OMIDRIA. Postoperative NSAIDS could be reduced from 10 to 4 weeks when OMIDRIA was used on the patient with no increase in CME, iritis, pain or photophobia1.
- With high-risk patients, OMIDRIA has been shown to significantly decrease to all three facets of IFIS: A rigorous, non-funded double-blind study by Dr. Silverstein determined that iris prolapse, billowing and flaccidity were dramatically reduced in severity and excursion when men on Tamsulosin received OMIDRIA in their irrigation solution for their cataract surgery. And as before, there was significantly less need for postoperative medications where OMIDRIA was used3.
- Dropless cataract surgery has a number of benefits: Improved patient compliance; reduced need for additional pain medication; and fewer postoperative complications.
OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.
IMPORTANT SAFETY INFORMATION
OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.
Please see the Full Prescribing Information for OMIDRIA.
- Controlling Postoperative Inflammation and Associated Complications with OMIDRIA
By Dr. Denise Visco
- Pain control and the reduction of opioid use associated with intracameral phenylephrine 1.0%-ketorolac 0.3% administered during cataract surgery
By Dr. Eric Donnenfeld, et al.
- Effect of phenylephrine 1.0%-ketorolac 0,3% injection on tamsulosin-associated intraoperative floppy-iris syndrome
By Steven Silverstein, et al.